Document and Entity Information
Document and Entity Information | Jun. 03, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Jun. 3, 2021 |
Entity Registrant Name | Viridian Therapeutics, Inc.\DE |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36483 |
Entity Tax Identification Number | 47-1187261 |
Entity Address, Address Line One | 6200 Lookout Rd. |
Entity Address, City or Town | Boulder |
Entity Address, State or Province | CO |
Entity Address, Postal Zip Code | 80301 |
City Area Code | 720 |
Local Phone Number | 643-5200 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value |
Trading Symbol | VRDN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | On June 4, 2021, Viridian Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting the voting results from the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Original Form 8-K also reported that the Annual Meeting was adjourned until June 11, 2021 with respect the voting on Proposal 4 (the “Reconvened Meeting”). The purpose of this amendment to the Original Form 8-K is to amend and supplement the Original Form 8-K to report the final meeting results from the Reconvened Meeting and the filing of a certificate of amendment to the Company’s restated certificate of incorporation in connection with the approval of Proposal 4. |
Current Fiscal Year End Date | --12-31 |
Amendment Flag | true |
Entity Central Index Key | 0001590750 |